Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes

American Journal of Pathology

Volumn 186, Issue 5, 2016, Pages 1103-1113

  Murakami, Ryusuke ^a   Matsumura, Noriomi ^a   Mandai, Masaki ^a,b   Yoshihara, Kosuke ^c   Tanabe, Hiroshi ^d   Nakai, Hidekatsu ^b   Yamanoi, Koji ^a   Abiko, Kaoru ^a   Yoshioka, Yumiko ^a   Hamanishi, Junzo ^a   Yamaguchi, Ken ^a   Baba, Tsukasa ^a   Koshiyama, Masafumi ^a   Enomoto, Takayuki ^c   Okamoto, Aikou ^d   Murphy, Susan K ^e   Mori, Seiichi ^f   Mikami, Yoshiki ^g   Minamiguchi, Sachiko ^h   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CANCER INSTITUTE   (Japan)

^g KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^h KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNITY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VERY ELDERLY; CELL PROLIFERATION; CLASSIFICATION; CLINICAL TRIAL; CYSTADENOCARCINOMA; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OBSERVER VARIATION; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OBSERVER VARIATION; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84964039826     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2015.12.029     Document Type: Article

References (30)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
2. J.D. Seidman, I. Horkayne-Szakaly, M. Haiba, C.R. Boice, R.J. Kurman, and B.M. Ronnett The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin Int J Gynecol Pathol 23 2004 41 44
3. D.S. Miller, J.A. Blessing, C.N. Krasner, R.S. Mannel, P. Hanjani, M.L. Pearl, S.E. Waggoner, and C.H. Boardman Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J Clin Oncol 27 2009 2686 2691
4. S.G. Silverberg Histopathologic grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol 19 2000 7 15
5. R. Vang, M. Shih Ie, and R.J. Kurman Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Adv Anat Pathol 16 2009 267 282
6. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, D.M. Gershenson, and E.G. Silva Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
7. G. Singer, R.J. Kurman, H.W. Chang, S.K. Cho, and M. Shih Ie Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 2002 1223 1228
8. D.C. Bodurka, M.T. Deavers, C. Tian, C.C. Sun, A. Malpica, R.L. Coleman, K.H. Lu, A.K. Sood, M.J. Birrer, R. Ozols, R. Baergen, R.E. Emerson, M. Steinhoff, B. Behmaram, G. Rasty, and D.M. Gershenson Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study Cancer 118 2012 3087 3094
9. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 10 2010 803 808
10. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
11. R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, et al. Cancer Genome Atlas Research Network Prognostically relevant gene signatures of high-grade serous ovarian carcinoma J Clin Invest 123 2013 517 525
12. R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, S. Lade, D.S. Johnson, M.K. Trivett, D. Etemadmoghadam, B. Locandro, N. Traficante, S. Fereday, J.A. Hung, Y.E. Chiew, I. Haviv Australian Ovarian Cancer Study Group D. Gertig, A. DeFazio, and D.D. Bowtell Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin Cancer Res 14 2008 5198 5208
13. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, D. Aoki, H. Tsuda, T. Sugiyama, S. Kodama, E. Kimura, K. Ochiai, K. Noda Japanese Gynecologic Oncology Group Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
14. + T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 2007 3360 3365
15. A.A. Ahmed, A.D. Mills, A.E. Ibrahim, J. Temple, C. Blenkiron, M. Vias, C.E. Massie, N.G. Iyer, A. McGeoch, R. Crawford, B. Nicke, J. Downward, C. Swanton, S.D. Bell, H.M. Earl, R.A. Laskey, C. Caldas, and J.D. Brenton The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel Cancer Cell 12 2007 514 527
16. K. Abiko, M. Mandai, J. Hamanishi, Y. Yoshioka, N. Matsumura, T. Baba, K. Yamaguchi, R. Murakami, A. Yamamoto, B. Kharma, K. Kosaka, and I. Konishi PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction Clin Cancer Res 19 2013 1363 1374
17. K. Yoshihara, A. Tajima, T. Yahata, S. Kodama, H. Fujiwara, M. Suzuki, Y. Onishi, M. Hatae, K. Sueyoshi, H. Fujiwara, Y. Kudo, K. Kotera, H. Masuzaki, H. Tashiro, H. Katabuchi, I. Inoue, and K. Tanaka Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets PLoS One 5 2010 e9615
18. A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci U S A 102 2005 15545 15550
19. D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn, A.C. Schinzel, P. Sandy, E. Meylan, C. Scholl, S. Frohling, E.M. Chan, M.L. Sos, K. Michel, C. Mermel, S.J. Silver, B.A. Weir, J.H. Reiling, Q. Sheng, P.B. Gupta, R.C. Wadlow, H. Le, S. Hoersch, B.S. Wittner, S. Ramaswamy, D.M. Livingston, D.M. Sabatini, M. Meyerson, R.K. Thomas, E.S. Lander, J.P. Mesirov, D.E. Root, D.G. Gilliland, T. Jacks, and W.C. Hahn Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 112
20. K. Yoshihara, T. Tsunoda, D. Shigemizu, H. Fujiwara, M. Hatae, H. Fujiwara, H. Masuzaki, H. Katabuchi, Y. Kawakami, A. Okamoto, T. Nogawa, N. Matsumura, Y. Udagawa, T. Saito, H. Itamochi, M. Takano, E. Miyagi, T. Sudo, K. Ushijima, H. Iwase, H. Seki, Y. Terao, T. Enomoto, M. Mikami, K. Akazawa, H. Tsuda, T. Moriya, A. Tajima, I. Inoue, K. Tanaka Japanese Serous Ovarian Cancer Study Group High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway Clin Cancer Res 18 2012 1374 1385
21. W.T. Hwang, S.F. Adams, E. Tahirovic, I.S. Hagemann, and G. Coukos Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis Gynecol Oncol 124 2012 192 198
22. D. Yang, Y. Sun, L. Hu, H. Zheng, P. Ji, C.V. Pecot, Y. Zhao, S. Reynolds, H. Cheng, R. Rupaimoole, D. Cogdell, M. Nykter, R. Broaddus, C. Rodriguez-Aguayo, G. Lopez-Berestein, J. Liu, I. Shmulevich, A.K. Sood, K. Chen, and W. Zhang Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer Cancer Cell 23 2013 186 199
23. L. Cao, M. Shao, J. Schilder, T. Guise, K.S. Mohammad, and D. Matei Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer Oncogene 31 2012 2521 2534
24. D.J. Cheon, Y. Tong, M.S. Sim, J. Dering, D. Berel, X. Cui, J. Lester, J.A. Beach, M. Tighiouart, A.E. Walts, B.Y. Karlan, and S. Orsulic A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer Clin Cancer Res 20 2014 711 723
25. K.H. Yew, J. Crow, J. Hirst, Z. Pressetto, and A.K. Godwin Epimorphin-induced MET sensitizes ovarian cancer cells to platinum PLoS One 8 2013 e72637
26. A.M. Haslehurst, M. Koti, M. Dharsee, P. Nuin, K. Evans, J. Geraci, T. Childs, J. Chen, J. Li, J. Weberpals, S. Davey, J. Squire, P.C. Park, and H. Feilotter EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer BMC Cancer 12 2012 91
27. J. Tan, Y. You, T. Xu, P. Yu, D. Wu, H. Deng, Y. Zhang, and P. Bie Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT Toxicol Lett 224 2014 7 15
28. T. Arumugam, V. Ramachandran, K.F. Fournier, H. Wang, L. Marquis, J.L. Abbruzzese, G.E. Gallick, C.D. Logsdon, D.J. McConkey, and W. Choi Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res 69 2009 5820 5828
29. D.S. Hsu, H.Y. Lan, C.H. Huang, S.K. Tai, S.Y. Chang, T.L. Tsai, C.C. Chang, C.H. Tzeng, K.J. Wu, J.Y. Kao, and M.H. Yang Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer Clin Cancer Res 16 2010 4561 4571
30. D. Tamura, T. Arao, T. Nagai, H. Kaneda, K. Aomatsu, Y. Fujita, K. Matsumoto, M.A. De Velasco, H. Kato, H. Hayashi, S. Yoshida, H. Kimura, Y. Maniwa, W. Nishio, Y. Sakai, C. Ohbayashi, Y. Kotani, Y. Nishimura, and K. Nishio Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells Cancer Med 2 2013 144 154